|
1
|
Shah RP, Shafiq A, Hamza M, Maniya MT, Duhan S, Keisham B, Patel B, Alamzaib SM, Yashi K, Uppal D, Sattar Y, Tiwari D, Paul TK, AlJaroudi W, Alraies MC. Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Am J Cardiol 2023; 207:206-214. [PMID: 37751668 DOI: 10.1016/j.amjcard.2023.08.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Revised: 08/16/2023] [Accepted: 08/20/2023] [Indexed: 09/28/2023]
Abstract
Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. Online databases, including MEDLINE and Cochrane Central, were queried to compare these drugs. The primary outcomes of this meta-analysis are myocardial infarction (MI), all-cause mortality, cardiovascular mortality, noncardiovascular mortality, stent thrombosis, and stroke. The secondary outcome is major bleeding. A total of 9 studies, including 94,590 patients (prasugrel group = 32,759; ticagrelor group = 61,831), were included in this meta-analysis. The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respectively. Prasugrel is equally effective as compared with ticagrelor in preventing MI. There was no difference between the 2 groups regarding all-cause mortality, stent thrombosis, stroke, or major bleeding. In patients with acute coronary syndrome, prasugrel is equally effective when compared with ticagrelor in preventing MI.
Collapse
Affiliation(s)
- Rajendra P Shah
- Department of Cardiology, University of Florida/Malcom Randall Veterans Affairs Medical Center, Florida, USA
| | - Aimen Shafiq
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
| | - Mohammad Hamza
- Department of Medicine, Albany Medical Center, Albany, New York, USA
| | | | - Sanchit Duhan
- Department of Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
| | - Bijeta Keisham
- Department of Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
| | - Bansari Patel
- Department of Medicine, West Virginia University, West Virginia, USA
| | | | - Kanica Yashi
- Department of Medicine, Bassett Healthcare, New York, USA
| | - Dipan Uppal
- Department of Cardiology, Cleveland Clinic Florida, Florida, USA
| | - Yasar Sattar
- Department of Cardiology, West Virginia University, Morgantown, West Virginia, USA
| | - Dinesh Tiwari
- Department of Dermatology, Mayo Institute of Medical Sciences, Uttar Pradesh, India
| | - Timir K Paul
- Department of Cardiology, University of Tennessee Health Sciences Center, Nashville, Tennessee, USA
| | - Wael AlJaroudi
- Division of Cardiology, Medical College of Georgia at Augusta University Medical College of Georgia, Augusta, Georgia, USA
| | - M Chadi Alraies
- Department of Cardiology, Cardiovascular Institute, Detroit Medical Center, Detroit, Michigan, USA.
| |
Collapse
|
|
2
|
Deseive S, Orban M. Choosing the right potent P2Y12-receptor inhibitor in East Asians with acute myocardial infarction and percutaneous coronary intervention - Editorial on Ticagrelor versus Prasugrel in patients with acute myocardial infarction. Int J Cardiol 2022; 347:17-18. [PMID: 34798208 DOI: 10.1016/j.ijcard.2021.11.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 11/11/2021] [Accepted: 11/12/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Simon Deseive
- Department of Medicine I, LMU-Klinikum, Ludwig-Maximilians-Universität München, Germany.
| | - Martin Orban
- Department of Medicine I, LMU-Klinikum, Ludwig-Maximilians-Universität München, Germany
| |
Collapse
|